Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017132474) BCL-2 INHIBITORS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/132474 International Application No.: PCT/US2017/015281
Publication Date: 03.08.2017 International Filing Date: 27.01.2017
Chapter 2 Demand Filed: 24.10.2017
IPC:
A61P 31/12 (2006.01) ,C07D 405/14 (2006.01) ,A61K 31/536 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12
Antivirals
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
405
Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
14
containing three or more hetero rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
535
having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
536
ortho- or peri-condensed with carbocyclic ring systems
Applicants:
NEWAVE PHARMACEUTICAL INC. [US/US]; 4695 Chabot Drive, Suite 200 Pleasanton, CA 94588, US
Inventors:
CHEN, Yi; US
LOU, Yan; US
Agent:
LU, Yu; US
BAI, Mei; US
ACETO, Donato; US
BARBIC, Andrej; US
BELT, Erik, P.; US
Priority Data:
62/289,20930.01.2016US
Title (EN) BCL-2 INHIBITORS
(FR) INHIBITEURS DE BCL-2
Abstract:
(EN) The disclosure includes compounds of Formula (I) wherein W, R1, R2, R3, R4, R5, R6, rn, n, L, and Z1, are defined herein. Also disclosed is a method for treating a neoplastic disease and autoimmune disease with these compounds.
(FR) La présente invention concerne des composés représentés par la formule (I) dans laquelle W, R1, R2, R3, R4, R5, R6, mn, n, L, et Z1 sont tels que définis dans la description. Elle concerne également une méthode de traitement d'une maladie néoplasique ou d'une maladie auto-immune à l'aide de ces composés.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)